Bibliografía del artículo
1. Gandhi MK, Tellman JT y Khanna R. Epstein-Barr virus-associated Hodgkin's lymphoma. Brit J Haematol 125:267-281, 2004.
2. Jaffe ES, Harris NL, Stein H y Vardiman JW. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. International Agency for Research and Cancer Press, Lyon, 2001.
3. Feugier P, Labouyrie E, Djeridane M y col. Comparison of initial characteristics and long-term outcome of patients with lymphocyte-predominant Hodgkin lymphoma and classical Hodgkin lymphoma at clinical stages IA and IIA prospectively treated by brief anthracycline-based chemotherapies plus extended high-dose irradiaton. Blood 104:2675-2681, 2004.
4. Lister TA, Crowther D, Sutcliffe SB y col. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Costwolds meeting. J Clin Oncol 7:1630-1636, 1989.
5. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease: International Prognostic Factors Project for Advanced Hodgkin´s Disease. N Eng J Med 339:1506-1514, 1998.
6. Pavlovsky S, Corrado CS, Pavlovsky MA, y col. Risk-adapted therapy with three or six cycles of doxorubicin/bleomycin/vinblastine/dacarbazine plus involved-field radiation therapy in Hodgkin lymphoma, Based on prognosis at diagnosis an early response. Results from the GATLA Study. Clin Lymphoma, Myeloma & Leukemia 10, 2010.
7. Gallamini A, Hutchings M, Rigacci L y col. Early interim 2-(18F) fluoro-2-deoxi-D glucose positron emission tomography is pronostically superior to International Prognostic Score in advanced-stage Hodgkin's lymphoma: A report from a joint Italian-Danish study. J Clin Oncol 25:3746-3752, 2007.
8. Hutchings M, Loft A Hansen M y Col. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 107:52-59, 2006.
9. Cheson BD, Pfistner, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 25:579-586, 2007.
10. De Vita VT. A selective history of the therapy of Hodgkin's disease. Brit J Haematol 122:718-727, 2003.
11. Pavlovsky S, Lastiri F. Progress in the prognosis of adult Hodgkin's lymphoma, in the past 35 years through clinical trials in Argentina. A GATLA experience. Clin Lymphoma 5:102-109, 2004.
12. Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327:1478-1484, 1992.
13. Duggan DB, Petroni GR, Johnson JL, et al. Randomized comparison of ABVD and MOPP/ABV hybryd for the treatment of advanced Hodgkin's disease: Report of an Intergroup Trial. J Clin Oncol 21:607-614, 2003.
14. Pavlovsky S, Schvartzman E, Lastiri F, et al. Randomized trial of CVPP for three versus six cycles in low risk and CVPP versus AOPE plus radiotherapy in intermediate-prognosis untreated Hodgkin's disease. J Clin Oncol 15:2652-2658, 1997.
15. Engert A, Schiller P, Josting A, et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: Results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 21:3601-3608, 2003.
16. Bonadonna G, Bonfante V, Simonetta V et al. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: Long-term results. J Clin Oncol 22:2396-2406, 2004.
17. Pavlovsky S, Maschio M, Santarelli MT, et al. Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for stage I-II Hodgkin's disease. J Natl Cancer Inst 80:1466-1473, 1988.
18. Strauss DJ, Portlock CS, Qin J, et al. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA non-bulky Hodgkin's disease. Blood 104:3483-3489, 2004.
19. Meyer RM, Gospodarowicz MK, Connors JM, et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited stage Hodgkin's lymphoma: National Cancer Institute of Canada, Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 23:21, 2005.
20. Aleman BMP, Raemaekers JMM, Tirelli U et al. Involved-field radiotherapy for advanced Hodgkin's lymphoma. N Eng J Med 348:2396-2406, 2003.
21. Graca MD, Metayer C, Curtis RE, et al. Second malignant neoplasms among long-term survivors of Hodgkin's disease: A population-based evaluation over 25 years. J Clin Oncol 20:3484-3494, 2002.
22. Horning SJ, Hoppe RT, Breslin S, et al. Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. J Clin Oncol 20:630-637, 2002.
23. Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 384:2386-2395, 2003.
24. Moskowitz CH, Kewalramani T, Nimer SD, et al. Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease. Brit J Haematol 124:645-652, 2004.
25. Federico M, Bellei M, Brice P, et al. High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy. J Clin Oncol 21:2320-2325, 2003.